Leerink Partners Remains Bullish on Five Prime Therapeutics (FPRX) Following announced Agreement with BMY

Oppenheimer Raises Price Target Following Five Prime Therapeutics' (FPRX) Announced Licensing Agreement with BMY

Oppenheimer reiterated an Outperform rating on Five Prime Therapeutics (NASDAQ: FPRX), and raised the price target to $48.00 (from $45.00), following the company's Oct. 15th announcement of a licensing agreement for FPA008 with BMY. FPRX will receive $350M cash upfront and is eligible for an additional $1.39B in development/regulatory... More

Notable 52-Week Highs and Lows 10/15: (FPRX) (NKE) High; (STX) (MTW) (GRMN) Low

52-Week High:Five Prime Therapeutics, Inc. (Nasdaq: FPRX) $28.48. Ahead of the opening bell, Bristol-Myers Squibb and Five Prime Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Primes colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1... More

Bristol-Myers Squibb (BMY) Names New Business Development SVP

Bristol-Myers Squibb (NYSE: BMY) announced that Paul Biondi has been appointed senior vice president, head of Business Development and will report to Charlie Bancroft, chief financial officer. In this role, Biondi will lead the development of strategic partnerships and pursue scientific innovations across commercial, development, discovery and technology platforms to complement the companys internal R&D pipeline. Biondi most recently served as senior vice president, head of R&D Operations, Bristol-Myers Squibb.

Paul has established himself as a dynamic and collaborative leader at Bristol-Myers Squibb and made... More

Unusual 11 Mid-Day Movers 10/15: (FPRX) (AFMD) (DXCM) Higher; (IMPR) (VAC) (ACST) Lower

Five Prime Therapeutics, Inc.(Nasdaq: FPRX) 63.0% HIGHER; Bristol-Myers Squibb Company and Five Prime Therapeutics announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Primes colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications. This agreement replaces the companies existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibbs programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor... More

Pre-Open Stock Movers 10/15: (FPRX) (BOFI) (DXCM) Higher; (IMPR) (MTW) (VRX) (STX) (GRMN) (HCA) (NFLX) Lower (more...)

Five Prime Therapeutics, Inc.(Nasdaq: FPRX) 70% HIGHER; Bristol-Myers Squibb Company (NYSE:... More

Five Prime Therapeutics (FPRX) Sees Windfall on Anti-CSF1R Collaboration Agreement (BMY)

Five Prime Therapeutics, Inc.(Nasdaq: FPRX) shares are ripping early following news that the company entered an... More

Five Prime Therapeutics (FPRX) Enters Collaboration with Bristol-Myers Squibb (BMY) Worth Up to $1.74B

Bristol-Myers Squibb Company (NYSE: BMY) and Five Prime Therapeutics, Inc.(Nasdaq: FPRX) today announced that they have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of Five Primes colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008 which is in Phase 1 development for immunology and oncology indications. This agreement replaces the companies existing clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibbs programmed-death 1 (PD-1) immune checkpoint inhibitor, with FPA008 in six tumor... More